Overview

* Balchem ( BCPC ) Q3 net sales rise 11.5% yr/yr, beating analysts' expectations

* Adjusted EPS rises to $1.35 from $1.13, beating estimates

* Company to build new facility in NY, doubling microencapsulation capacity

Outlook

* Company did not provide specific financial guidance for future quarters or full year

Result Drivers

* MARKET PENETRATION - Co attributes strong growth to increased market penetration of specialty nutrients and delivery systems

* SEGMENT GROWTH - All three reporting segments showed sales and earnings growth, driven by higher sales and favorable mix

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $267.60 $258.28

mln mln (3

Analysts

)

Q3 Beat $1.35 $1.31 (2

Adjusted Analysts

EPS )

Q3 EPS $1.24

Q3 Net $40.30

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialty chemicals peer group is "buy"

* Wall Street's median 12-month price target for Balchem Corp ( BCPC ) is $192.00, about 21.5% above its October 20 closing price of $150.77

* The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)